Intensified treatment with triplet chemotherapy (FOLFOXIRI) combined with panitumumab was evaluated in phase II trial VOLFI, a numerical trend towards improved OS was noted. 63 The panel prefers waiting for more solid and long-term data before approving this treatment option, currently, it is not recommended.
← all excerpts
Resource Oriented Decision Making for Treatment of Metastatic Colorectal Cancer (mCRC) in a Lower-Middle Income Country: Egyptian Foundation of Medical Sciences (EFMS) Consensus Recommendations 2020.
1
—
—